HONG KONG – American firm Personal Genome Diagnostics Inc. (PGDx) has partnered with China laboratory services provider Guangzhou Kingmed Diagnostics Group Co. Ltd. (Kingmed) to commercialize the cancer detection product PGDx elio assays on the Chinese mainland and in Hong Kong.
HONG KONG – After inking a deal last year worth $83 million with Swedish biotech firm Pledpharma AB to acquire the exclusive rights to develop and commercialize Pledox, Japan's Solasia Pharma KK has started the molecule's phase III development in Asia. It's part of a global phase III trial testing the compound, which is used to suppress the development of peripheral neuropathy in colorectal cancer patients.
HONG KONG – After inking a deal last year worth $83 million with Swedish biotech firm Pledpharma AB to acquire the exclusive rights to develop and commercialize Pledox, Japan's Solasia Pharma KK has started the molecule's phase III development in Asia. It's part of a global phase III trial testing the compound, which is used to suppress the development of peripheral neuropathy in colorectal cancer patients.
HONG KONG – American firm Personal Genome Diagnostics Inc. (PGDx) has partnered with China laboratory services provider Guangzhou Kingmed Diagnostics Group Co. Ltd. (Kingmed) to commercialize the cancer detection product PGDx elio assays on the Chinese mainland and in Hong Kong.
HONG KONG – China bioprocessing technology firm Hangzhou Just Biotherapeutics Ltd. (HJB) and clinical-stage biotech Mabspace Biosciences Co. Ltd. have entered a merger agreement to establish a biotherapeutics maker, Transcenta Holding Ltd., with the aim of shortening the time from target to biologics license applications, and setting up a next-generation GMP facility that supports the development and commercialization of molecules both in-house and from its partners.
